Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Diagnostika ir moksliniai tyrimai

Ms. Nicole  Lambert

Consultant

Mr. Samraat S. Raha

Chief Operating Officer

Mr. Paul J. Diaz

Chief Executive Officer, President & Director

Mr. R. Bryan Riggsbee

Strategic Advisor

Mr. Scott J. Leffler

Chief Financial Officer

Mr. Matthew  Scalo

Senior Vice President of Investor Relations

Dr. Kevin Richard Haas Ph.D.

Chief Technology Officer

Mr. Mark S. Verratti

Chief Commercial Officer

Ms. Natalie  Munk

Principal Accounting Officer

Dr. Dale  Muzzey Ph.D.

Chief Scientific Officer

Pavadinimas	Rinkos kapitalizacija
Thyrocare Technologies Limited	0M
HTG Molecular Diagnostics, Inc.	0M
Global Cord Blood Corporation	0M
ANGLE plc	0M
Diaceutics PLC	0M
Centogene N.V.	0M
DermTech, Inc.	0M
HTG Molecular Diagnostics, Inc.	0M
SQI Diagnostics Inc.	0M

Myriad Genetics, Inc.

Myriad Genetics, Inc. Konkurentų sąrašas

Pagrindiniai konkurentai